Skip to main content
Premium Trial:

Request an Annual Quote

Macrogen Receives South Korean Accreditation

NEW YORK (GenomeWeb) – South Korea's Macrogen announced recently that it received Good Clinical Laboratory Practice accreditation from that country's Ministry of Food and Drug Safety (MFDS.)

GCLP is a quality standard for labs that analyze blood and urine sample for clinical trials, Macrogen said. The designation will enable the firm to perform next-generation sequencing analyses on clinical trial samples. The firm said in a statement that it is the first and only lab in South Korea that is able to work with NGS on such samples.

As a result of its position, the firm said it expects "to attract, as potential clients, domestic, and multinational pharmaceutical companies that develop drugs for the Korean market," especially new anti-cancer drug candidates along with companion diagnostics.

"As the pharmaceutical industry became aware of Macrogen's impending designation as an authorized institute, reservation inquiries for NGS analyses by multinational pharmaceutical companies have continued to increase," Macrogen CEO Kap-Seok Yang said in a statement.

Macrogen registered as a genetic testing agency in 2005 and in 2017 it acquired NGS Clinical Laboratory certification from MFDS. The firm has also obtained CAP and CLIA accreditation for its NGS Clinical Labs and Bundang Precision Medicine Center. In February, the firm obtained GMP certification for its NGS-based in vitro diagnostic reagent production facility.

According to Macrogen, South Korean law requires that all clinical trial sample analyses be conducted by an accredited lab authorized by the MFDS.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.